<DOC>
	<DOC>NCT00308308</DOC>
	<brief_summary>To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes</brief_summary>
	<brief_title>Efficacy &amp; Safety of Inhaled Insulin in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Clinical diagnosis of type 1 diabetes for at least 1 year Nonsmokers for prior 6 months BMI less than or equal to 35kg/m2 HbA1c &gt; or = 7% and &lt; or = 11% Serum creatinine &lt; or = 1.8 mg/dL in female subjects and &lt; or = 2.0 mg/dL in male subjects FEV1 &gt; or = 70% of predicted, DLco &gt; or = 70% , TLC &gt; or = 80% predicted Maintenance of a treatment regimen of insulin less than or equal to 1.4 iu/kg/day Urine cotinine &lt; or = 100 ng/mL History of chronic obstructive pulmonary disease, asthma, any other clinically significant pulmonary disease confirmed by documented history, pulmonary function testing or radiologic findings Evidence of severe complications of diabetes Aminotransferase and/or alanine aminotransferase &gt; than 3 times the upper limit of normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>